Shares of CureVac (CVAC) were up 1.2% in premarket trading on Wednesday after the company said it dosed the first participant in a Phase 1 clinical trial for the new mRNA COVID-19 vaccine it's developing with GlaxoSmithKline (GSK.LN). The study is being conducted in the U.S. and is set to enroll 210 adults. The company said it expects to have data in the second half of this year. "Continued innovation and progress in the development of mRNA-based vaccines is a critical prerequisite to combat the evolving COVID-19 pandemic," Dr. Klaus Edvardsen, CureVac's chief development officer, said in a news release. CureVac's stock has tumbled 44.0% this year, while the S&P 500 is up 2.8%. fdsup://factset/Doc%20Viewer%20Single?_expand=nE9Id5&float_window=true
(END) Dow Jones Newswires
03-30-22 0754ETCopyright (c) 2022 Dow Jones & Company, Inc.